Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
Transdermal Lisuride: a Double-blind, Randomized, Active- and Placebo-controlled Multi-centre Phase III Efficacy Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
Sponsor: Axxonis Pharma AG
A PHASE3 clinical study on Restless Legs Syndrome, this trial is completed. The trial is conducted by Axxonis Pharma AG and has accumulated 5 data snapshots since 2026. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Axxonis Pharma AG
For direct contact, visit the study record on ClinicalTrials.gov .